Is Upadacitinib a hormonal drug?

Upadacitinib (Upadacitinib) is not a hormonal drug. It is a selective JAK1 inhibitor, mainly used to treat rheumatoid arthritis, ankylosing spondylitis, moderate to severe ulcerative colitis and other diseases. Large Phase III programs, including the U-ACHIEVE and U-ACHIEVE parallel induction trials and the U-ACHIEVE maintenance trial, demonstrated superiority to placebo across all primary and secondary endpoints, including key clinical, endoscopic and histological outcomes.

The dosage of upadatinib is 45 mg orally once a day (OD) during the induction period, and 30 mg or 15 mg orally during the maintenance period. From a safety perspective, upadatinib has been shown to be a safe and well-tolerated drug for immune-mediated diseases, with manageable adverse risks, such as an increase in herpes zoster. Appropriate physician discussion and patient characterization are critical when positioning upadacitinib, given the efficacy and potential risks associated with this highly potent drug.

The original drug Upatinib has been launched in China, and has subsequently entered the scope of Class B medical insurance. Only eligible patients can be reimbursed. Specifications The price of each box of 15mg*28 tablets may be around RMB 3,000. The European version of the original drug sold overseas is priced at more than 20,000 yuan for 15mg*30 tablets (the price may fluctuate due to exchange rates), which is expensive. Cheaper upadatinib generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 15mg*30 tablets produced by Bangladesh pharmaceutical factory is around 900 yuan (the price may fluctuate due to the exchange rate).